Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
ArriVent BioPharma, Inc. (AVBP) had Income from Continuous Operations of $-64.39M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-64.39M |
|
-- |
|
-- |
|
$66.77M |
|
$-66.77M |
|
$2.38M |
|
$-64.39M |
|
$-64.39M |
|
$-64.39M |
|
|
Income from Continuous Operations |
$-64.39M |
$-64.39M |
|
$-64.39M |
|
$-66.77M |
|
$-66.77M |
|
33.90M |
|
33.90M |
|
$-1.90 |
|
$-1.90 |
|
| Balance Sheet Financials | |
$185.78M |
|
-- |
|
$29.71M |
|
$215.50M |
|
$12.95M |
|
-- |
|
-- |
|
$12.95M |
|
$202.54M |
|
$202.54M |
|
$202.54M |
|
34.04M |
|
| Cash Flow Statement Financials | |
$-68.01M |
|
$36.82M |
|
$6.76M |
|
$74.29M |
|
$49.87M |
|
$-24.43M |
|
$2.27M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
14.34 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-68.01M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-31.79% |
|
-31.79% |
|
-29.88% |
|
-31.79% |
|
$5.95 |
|
$-2.01 |
|
$-2.01 |
|